Kush medical laboratories

25/12/2025

25/12/2024

You are special to us.

01/01/2024

HAPPY PROSPEROUS NEW YEAR, 2024.

10/12/2023

‘’Surely God’s goodness and His mercy shall follow me all the days of my life …”

30/09/2022

Memories 🤣🤣🤣

05/06/2022

God !
😭😭😭

27/03/2022

Happy mothers day

16/08/2021

Repost from
Source: National Institutes of Health.

A new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to 9 months in people who were exposed to the malaria parasite.
The small clinical trial is the first to show an antibody capable of preventing malaria in people. The trial was sponsored and conducted by scientists from the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases and was funded by NIAID.
"Malaria continues to be a major cause of illness and death in many regions of the world, especially in infants and young children; therefore, new tools are needed to prevent this deadly disease," said NIAID Director Anthony Fauci, MD. "The results reported today suggest that a single infusion of a monoclonal antibody can protect people from malaria for at least 9 months. Additional research is needed, however, to confirm and extend this finding."
The study was published Thursday(13th August, 2021) in The New England Journal of Medicine.
An estimated 229 million cases of malaria occurred worldwide in 2019, resulting in an estimated 409,000 deaths, mostly in children in sub-Saharan Africa.

16/08/2021

Source: National Institutes of Health.
A new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to 9 months in people who were exposed to the malaria parasite.
The small clinical trial is the first to show an antibody capable of preventing malaria in people. The trial was sponsored and conducted by scientists from the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases and was funded by NIAID.
"Malaria continues to be a major cause of illness and death in many regions of the world, especially in infants and young children; therefore, new tools are needed to prevent this deadly disease," said NIAID Director Anthony Fauci, MD. "The results reported today suggest that a single infusion of a monoclonal antibody can protect people from malaria for at least 9 months. Additional research is needed, however, to confirm and extend this finding."
The study was published Thursday(13th August, 2021) in The New England Journal of Medicine.
An estimated 229 million cases of malaria occurred worldwide in 2019, resulting in an estimated 409,000 deaths, mostly in children in sub-Saharan Africa.